Information between 18th October 2025 - 28th October 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
20 Oct 2025 - Diego Garcia Military Base and British Indian Ocean Territory Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 297 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 83 Noes - 319 |
|
20 Oct 2025 - Diego Garcia Military Base and British Indian Ocean Territory Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 298 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 174 Noes - 321 |
|
20 Oct 2025 - Diego Garcia Military Base and British Indian Ocean Territory Bill - View Vote Context Alistair Strathern voted Aye - in line with the party majority and in line with the House One of 296 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 320 Noes - 171 |
|
20 Oct 2025 - Diego Garcia Military Base and British Indian Ocean Territory Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 299 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 172 Noes - 322 |
|
20 Oct 2025 - Diego Garcia Military Base and British Indian Ocean Territory Bill - View Vote Context Alistair Strathern voted Aye - in line with the party majority and in line with the House One of 298 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 318 Noes - 174 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 282 Labour No votes vs 2 Labour Aye votes Tally: Ayes - 77 Noes - 390 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 297 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 167 Noes - 313 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 300 Labour No votes vs 1 Labour Aye votes Tally: Ayes - 182 Noes - 307 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted Aye - in line with the party majority and in line with the House One of 306 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 389 Noes - 102 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 304 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 105 Noes - 381 |
|
21 Oct 2025 - Sentencing Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 298 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 104 Noes - 317 |
|
27 Oct 2025 - Victims and Courts Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 310 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 153 Noes - 332 |
|
27 Oct 2025 - Victims and Courts Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 314 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 152 Noes - 337 |
|
27 Oct 2025 - Victims and Courts Bill - View Vote Context Alistair Strathern voted No - in line with the party majority and in line with the House One of 309 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 166 Noes - 322 |
| Written Answers |
|---|
|
Brain: Tumours
Asked by: Alistair Strathern (Labour - Hitchin) Monday 20th October 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all brain tumour patients are routinely informed of opportunities to take part in (a) research and (b) clinical trials. Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care) The Department is committed to ensuring that all patients, including those with brain tumours have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Department is ensuring that patients, including those with brain tumours, are informed about research opportunities relevant to them through 'Be Part of Research', a free service provided by the National Institute for Health and Care Research (NIHR) that allows people in the UK to search for research studies and register their interest. In addition, the Department funds research and research infrastructure across England through the NIHR which supports patients and the public to participate in high-quality research, including on brain tumours. The Government is also supporting the Rare Cancers Private Members Bill. The Bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers. |
|
Hyoscine Hydrobromide
Asked by: Alistair Strathern (Labour - Hitchin) Monday 20th October 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the supply of Hyoscine hydrobromide 1.5mg patches. Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care) The Department is aware that hyoscine hydrobromide (Scopoderm) 1.5 milligram patches are currently out of stock with a resupply date yet to be confirmed. We are continuing to work closely with the sole supplier of this product and the Medicines and Healthcare products Regulatory Agency to resolve this issue as soon as possible. The Department issued comprehensive management guidance to the National Health Service, including all general practices and community pharmacists, on 21 September 2023. This management guidance includes information on a variety of alternative licensed medicines, and should these not be suitable or appropriate, clinicians can consider prescribing unlicensed hyoscine hydrobromide (Scopoderm) 1.5 milligram patches. |